915 studies found for:    Open Studies | "Carcinoma, Bronchogenic"
Show Display Options
RSS Create an RSS feed from your search for:
Open Studies | "Carcinoma, Bronchogenic"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting SAS in Patients With Bronchial Carcinoma
Conditions: Sleep Apnea Syndrome;   Bronchial Carcinoma
Intervention: Device: sleep apnea screening with ApneaLinkTM
2 Recruiting Clinic Study of 18F-Al-NOTA-PRGD2 in Cancer Diagnostics
Conditions: Tumors;   Carcinoma, Bronchogenic;   Breast Carcinoma;   Cancer of Head and Neck;   Lymphoma, Malignant;   Soft Tissue Neoplasms
Intervention: Drug: 18F-Al-NOTA-PRGD2 PET/CT
3 Unknown  Efficacy and Safety Study of Gefitinib in Squamous NSCLC Patients Who Failed First-Line Chemotherapy
Condition: Squamous Cell Carcinoma of Bronchus
Intervention: Drug: Gefitinib
4 Unknown  Study to Determine the Efficacy of Bendamustin in Patients With Recurrent Small Cell Lung Cancer (SCLC)
Condition: Recurrent Small Cell Lung Cancer
Intervention: Drug: Bendamustin/Ribomustin
5 Recruiting Comparison of Different Types of Surgery in Treating Patients With Early-stage Non-small Cell Lung Cancer
Conditions: Stage IA Non-small Cell Lung Cancer;   Adenocarcinoma of the Lung;   Squamous Cell Lung Cancer
Intervention:
6 Recruiting Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)
Conditions: Lung Cancer;   Non-small Cell Lung Cancer (NSCLC)
Interventions: Drug: Dasatinib - 1A;   Drug: Afatinib - 1A;   Drug: Dasatinib - 1B;   Drug: Afatinib - 1B
7 Recruiting Study of Apatinib in RET Fusion Positive Advanced Non-small Cell Lung Cancer
Condition: Non-small Cell Lung Cancer
Intervention: Drug: Apatinib single agent arm
8 Not yet recruiting A Randomized, Multicenter, Double-Blind, Phase 3 Study of Nivolumab, Nivolumab in Combination With Ipilimumab, or Placebo as Maintenance Therapy in Subjects With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based First Line Chemotherapy
Condition: Lung Cancer
Interventions: Biological: Nivolumab;   Biological: Ipilimumab;   Other: Placebo
9 Recruiting Phase 1 Combination Study of MM-151 and MM-121
Conditions: Colorectal Cancer;   Non-small Cell Lung Cancer;   Squamous Cell Carcinoma of the Head and Neck
Interventions: Drug: MM-151;   Drug: MM-121
10 Not yet recruiting Phase II Trial of EP4 Receptor Antagonist, AAT-007 (RQ-07; CJ-023,423) in Advanced Solid Tumors
Conditions: Prostate Cancer;   Non-Small Cell Lung Cancer;   Breast Cancer
Interventions: Drug: RQ-00000007;   Drug: Gemcitabine
11 Not yet recruiting Talazoparib in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors
Conditions: Solid Tumors;   Carcinoma, Non-Small Cell Lung;   Non-Small Cell Lung Cancer;   Non-Small-Cell Lung Carcinoma;   Nonsmall Cell Lung Cancer
Interventions: Drug: Cisplatin;   Drug: Gemcitabine;   Drug: Talazoparib
12 Recruiting Efficacy and Safety of Pyrotinib in Patients With HER2 Mutation Advanced Non-Small Cell Lung Cancer
Condition: Non-small Cell Lung Cancer
Intervention: Drug: Pyrotinib
13 Not yet recruiting Erlotinib Hydrochloride and Hsp90 Inhibitor AT13387 in Treating Patients With Recurrent or Metastatic Non-small Cell Lung Cancer
Conditions: Recurrent Non-Small Cell Lung Carcinoma;   Stage IV Non-Small Cell Lung Cancer
Interventions: Drug: Erlotinib Hydrochloride;   Drug: Hsp90 Inhibitor AT13387;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
14 Not yet recruiting Methoxyamine, Pemetrexed Disodium, Cisplatin, and Radiation Therapy in Treating Patients With Stage IIIA-IV Non-small Cell Lung Cancer
Conditions: Metastatic Malignant Neoplasm in the Brain;   Stage IIIA Large Cell Lung Carcinoma;   Stage IIIA Lung Adenocarcinoma;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIB Large Cell Lung Carcinoma;   Stage IIIB Lung Adenocarcinoma;   Stage IIIB Non-Small Cell Lung Cancer;   Stage IV Large Cell Lung Carcinoma;   Stage IV Lung Adenocarcinoma;   Stage IV Non-Small Cell Lung Cancer
Interventions: Radiation: 3-Dimensional Conformal Radiation Therapy;   Drug: Cisplatin;   Radiation: Intensity-Modulated Radiation Therapy;   Other: Laboratory Biomarker Analysis;   Drug: Methoxyamine;   Drug: Pemetrexed Disodium
15 Not yet recruiting A Study of Pemetrexed Maintenance With or Without ADXS11-001 Immunotherapy in Patients With Human Papillomavirus Positive (HPV+), NSCLC Following First-Line Induction Chemotherapy
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: ADXS11-001;   Drug: Pemetrexed
16 Not yet recruiting Phase I, Study in Chinese NSCLC Patients
Condition: Carcinoma, Non-Small-Cell Lung With EGFR Mutation Positive
Interventions: Drug: AZD9291 40 mg;   Drug: AZD9291 80 mg
17 Recruiting Study of FPA008 in Combination With Nivolumab in Patients With Selected Advance Cancers
Conditions: Non-Small Cell Lung Cancer;   Melanoma;   Head and Neck Squamous Cell Cancer;   Pancreatic Cancer;   Colorectal Cancer;   Glioblastoma Multiforme
Interventions: Drug: FPA008;   Drug: Nivolumab
18 Not yet recruiting MPDL3280A With Chemoradiation for Lung Cancer
Conditions: Lung Cancer;   Non-Small Cell Lung Cancer
Interventions: Drug: MPDL3280A;   Drug: Carboplatin;   Drug: Paclitaxel;   Radiation: Radiation Therapy
19 Not yet recruiting ALT-803 Plus Nivolumab in Patients With Pretreated, Advanced or Metastatic Non-Small Cell Lung Cancer
Condition: Non-small Cell Lung Cancer
Interventions: Biological: ALT-803;   Biological: Nivolumab
20 Not yet recruiting An Open-label Phase Ib/II Study of BAY 1000394 (Roniciclib) in Combination With Docetaxel in Second- or Third-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
Condition: NSCLC (Non-Small Cell Lung Cancer)
Intervention: Drug: BAY 1000394 (Roniciclib) in combination with docetaxel

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years